Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Operating Leases (2019 - 2025)

CytomX Therapeutics (CTMX) has disclosed Operating Leases for 7 consecutive years, with $1.4 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Operating Leases fell 79.06% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Jun 2025, down 79.06%, and an annual FY2024 reading of $4.2 million, down 54.82% over the prior year.
  • Operating Leases was $1.4 million for Q2 2025 at CytomX Therapeutics, down from $2.9 million in the prior quarter.
  • Across five years, Operating Leases topped out at $20.8 million in Q1 2021 and bottomed at $1.4 million in Q2 2025.
  • Average Operating Leases over 5 years is $11.9 million, with a median of $12.3 million recorded in 2023.
  • The sharpest move saw Operating Leases fell 13.68% in 2021, then tumbled 79.06% in 2025.
  • Year by year, Operating Leases stood at $18.1 million in 2021, then fell by 22.6% to $14.0 million in 2022, then plummeted by 32.84% to $9.4 million in 2023, then tumbled by 54.82% to $4.2 million in 2024, then plummeted by 65.99% to $1.4 million in 2025.
  • Business Quant data shows Operating Leases for CTMX at $1.4 million in Q2 2025, $2.9 million in Q1 2025, and $4.2 million in Q4 2024.